Important news from European KCNQ2 research
January 2026
The European research initiative EDERA has announced the results of its first major funding program for preclinical therapy projects in rare diseases. As part of the Joint Transnational Call 2025, several promising projects were selected with the goal of advancing new therapeutic approaches from the laboratory toward clinical development.
Especially encouraging for the KCNQ2 community:
Projects directly related to KCNQ2 have been selected, including #VALUEKCNQ.
What does this mean?
The funded projects aim to:
- develop new therapeutic candidates for rare diseases,
- generate preclinical data (e.g. in cellular or animal models),
- and prepare promising approaches for future clinical studies.
For KCNQ2, this means:
➡️ targeted research into disease-relevant mechanisms
➡️ a focus on therapies beyond seizure control alone
➡️ an important step toward disease-modifying treatments
These projects bring together leading research institutions, clinicians, and experts from multiple European countries. Such international collaboration is essential to accelerate progress in rare diseases.
💜 We are very pleased to see KCNQ2 included in this important European funding initiative and will keep the community informed about further developments.
Yours sincerely,
The KCNQ2 e.V. team
Disclaimer
This post is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Preclinical research does not imply that a therapy will be available in the near future. For medical decisions, please consult qualified healthcare professionals. No liability is assumed for the accuracy, completeness, or timeliness of the information provided.